Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03422341 · ClinicalTrials.gov registry record · NA

Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs.

A NA study, sponsored by Meridian Bioscience.

Completed
Registry status
NA
Development phase
497
Enrollment target

NCT03422341 is a NA study that has completed, run by Meridian Bioscience. The registered enrollment target is 497 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03422341, a NA study, has completed, sponsored by Meridian Bioscience.

COMPLETED
Registry status
NA
Development phase
497 participants
Enrollment target

Study Summary

The primary purpose of this clinical investigation is to establish the performance of the GenePOC Strep A, C/G assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Group A β-hemolytic Streptococcus (GAS) and pyogenic Group C and G β-hemolytic Streptococcus (GCS/GGS) in throat swab samples.

Interventions

  • DEVICE Comparison between GenePOC CR and Reference Method

Trial Details

FieldValue
Enrollment Target 497 participants
Start Date 2018-02-14
Est. Completion 2018-07-11
Phase NA

Sponsor

Meridian Bioscience

19 total trials

What the Registry Record Tells You About NCT03422341

The ClinicalTrials.gov registry entry for NCT03422341 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 497 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Comparison between GenePOC CR and Reference Method is the first listed.

NCT03422341 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03422341 about?

NCT03422341 is a clinical study titled "Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs.". The primary purpose of this clinical investigation is to establish the performance of the GenePOC Strep A, C/G assay on the revogene. This will be achieved by comparing the test to a conventional method for detection of Group A β-hemolytic Streptococcus (GAS) and pyogenic Group C and G β-hemolytic S...

What is the current status of trial NCT03422341?

This trial is currently completed. It is a NA study. The enrollment target is 497 participants. The study started on 2018-02-14. Estimated completion is 2018-07-11.

What interventions are being tested in trial NCT03422341?

The interventions under investigation include: Comparison between GenePOC CR and Reference Method (DEVICE).

Who is sponsoring clinical trial NCT03422341?

This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.